Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment
Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings.
Point of interest is psychopathology and consumerism.
|Psychotic Disorders Marijuana Abuse Intervention||Behavioral: Cannabis-Consumption-Reduction-Training Behavioral: Social competence Training||Phase 1|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis|
- PANSS Positive and Negative Symptom Scale [ Time Frame: post intervention, six months follow-up ]
- Urinstatus for cannabinoids [ Time Frame: weekly during and post intervention, follow-up ]
|Study Start Date:||January 2006|
|Study Completion Date:||January 2010|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
Active Comparator: CG
Behavioral: Social competence Training
8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients.
Cannabis misuse is a known risk factor for recurrence of psychosis.
A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital.
The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well).
Admission to groups is randomly.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00783185
|University of Konstanz|
|Konstanz, Baden-Württemberg, Germany, 78462|
|Principal Investigator:||Hans Watzl, Dr.||University of Konstanz|